Again about HER-Vaxx, the commercial application was also going...

First 23 Last

Share
Profile

Follow
AlCp

26,267 Posts.

1709

21/04/24

14:32

Post #: 73444385
Share

Originally posted by Mason14 ↑

This is the height of misleading pseudoscience biased garbage.

Can someone from the group of 34 post the professors analysis on the HER-vaxx data? If possible, separate p1b and p2, as they are similar but have unique weaknesses. If the professor was great, he would have seen what I and IMU management saw.

The single cholangiocarcinoma patient is not the mean, it's the outlier. The average of the data set so far points to ineffectiveness and I am not confident that increasing the dose is going to produce more effect.

Pexa-Vec is an OV therapy within the same poxviridae family as CF33. Let's play a game - here are the results from a P1 trial of Pexa-vec in liver cancer to find the optimal p2 dose in comparison to IMUs CF33 data to date.

Can you guess which compound is 1 and 2? More than 85% of the time, both drugs fail to achieve a meaningful response. The clear weakness of the P1 Pexa-vec data follows through to eventually proving that single agent Sorafenib outperforms combination Pexa+sorafenib in a P3 trial. What does that say about the future of CF33 and the three clinical programs? Risk.

Pexa-vec is from the same family of virus as CF33, though it is impossible to state whether dose ranges would be the same for each. In any case, a 10^9 appears to be the ceiling for Pexa. That data has not been released by IMU yet, so we will wait and see.

A lot of you are oblivious or maybe moreso ignorant to how much data is out there that is against the success of CF33 and OV therapy in general. I'm hoping that an increase in dose improves efficacy significantly and that there are no DLTs.

Compound 1: CF33
Compound 2: Pexa-vec

Expand

Again about HER-Vaxx, the commercial application was also going to be used to make Chemotherapy more effective by causing less side effect so the actual Chemotherapy doesn't cause the mortality and the current Ph2 clinical trial data demonstrate very good efficacy and no toxicity at all. If you invested for HER-Vaxx then you should have known it was never going to replace Chemotherapy, there's still a market for this as not all cancer treatment current and in the future will response to the treatment and Chemotherapy will be the last resort.

Again why are you comparing different virus?? Is solid tumour in liver more difficult to treat than Bile duct and isn't the response from patient with cholangiocarcinoma 2 from 2 (CR who has been longest on very low dosage and SD who has been 200 days behind the CR also on very low dosage)? Also, it looks like Ph1 of Pexa-Vec started a decade ago and Ph3 clinical trial failed in 5 years ago? You don't think there has been scientific advancement over a decade ago?????

IMU Price at posting: 7.1¢ Sentiment: None Disclosure: Held
16 Upvote

0 Great analysis

Reply